News
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023
Jaguar Health, Inc. reports a 20% increase in total net revenue for 2024, reaching $11.7 million. Expecting first results in Q2 2025 for crofelemer trials. FDA meeting scheduled for Phase 3 OnTarget trial -
-
-
COMMUNIQUÉ DE PRESSE
83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey
Jaguar Health's Canalevia-CA1 receives FDA approval for chemotherapy-induced diarrhea in dogs, addressing a critical unmet need in veterinary oncology -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
Napo Pharmaceuticals presents statistically significant responder analysis results for crofelemer in breast cancer patients at San Antonio Breast Cancer Symposium and MASCC, FDA Type C Meeting scheduled for 2025 -
